Biotech & Life Sciences

Oxford researchers built bacteria that kill drug-resistant pathogens two ways at once. The evolutionary math is different from any antibiotic ever made.

The finding came from a teaching moment gone sideways: a laser bleaching experiment produced a second dark line nobody expected. Inside that artifact was a new kind of cellular transport, fifty times faster than textbooks described.

The same industrial waste that pulp mills spend millions to dispose of could become a bone scaffold. In rats, a carbon-graphene material achieved nearly 90 percent repair in 30 days.

The 84% five-month rPFS looks encouraging until you notice the data comes from just 18 patients, the comparator arm is darolutamide rather than a stronger AR inhibitor, and Wall Street sold off 27% anyway.

The FDA opened a door for personalized CRISPR. The manufacturing requirements to actually approve a drug are on the other side of that path — and the first company to try it didn't make it.

Imagine running 160 experiments on pneumonia using a model of lung cancer, and being surprised when the drugs don't work.

Bhattacharya keeps citing a dead WWII science czar to justify dismantling the system that scientist built. Here is what Vannevar Bush actually believed — and why the NIH director is doing the opposite.

The FDA hit Orca Bio with a 3-month manufacturing delay — not a safety problem. The Phase 3 data remains striking: 78% of transplant patients alive without severe chronic GVHD at one year, versus 38.4% on the standard regimen.

Five children hit a wall during food allergy therapy. Then researchers added a cheap, generic asthma pill—and all 5 completed treatment.

The FDA is rewriting its approval rulebook not around patient need, but around a race with China — and the agency is losing that race on patient recruitment, trial speed, and new drug approvals.